医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KYOCERA to Acquire Japan-Based Showa Optronics Co., Ltd. to Strengthen Optical Components Business

2020年03月25日 PM09:00
このエントリーをはてなブックマークに追加


 

KYOTO, Japan

Kyocera Corporation (President: Hideo Tanimoto; hereunder: Kyocera) today announced that it entered into a share transfer agreement with NEC Corporation (President: Takashi Niino; hereunder: NEC) on March 25, 2020 to acquire all of NEC’s shares in Showa Optronics Co., Ltd., an optical components manufacturer (President: Minoru Hijikawa; hereunder: SOC). After the share transfer is completed, Kyocera will own 93.53% of SOC’s shares; SOC will begin operating as a subsidiary of Kyocera on June 1, 2020, under the name Kyocera Showa Optronics Co., Ltd. (KSO).

●Background Information and Objectives
With its highly advanced manufacturing technologies, Kyocera’s optical components business has engaged in producing diversified lenses in small to large diameters from a wide variety of materials. The products have been used in various fields, including automotive, office and factory automation equipment, and medical equipment, since Kyocera entered this business in 1983.

In 2016, Kyocera expanded this business by acquiring Japan-based Melles Griot KK, a manufacturer of large-diameter and high-precision lenses for factory automation equipment. The company is expanding its production capabilities to meet rising demand.

SOC, established in 1954, has targeted high-value-added markets including space-related products, semiconductor manufacturing equipment (such as exposure equipment), and medical equipment for DNA analysis, using its core technologies of ultra-high-precision lens polishing, high-proof and low-loss film formation, and lasers with outstanding stability.

In acquiring SOC as a subsidiary, Kyocera aims to become a leading optical components company by expanding its new product offerings in the laser market, maximizing synergies through both companies’ combined technologies, and utilizing Kyocera’s worldwide sales network and production facilities to further expand its optical components businesses.

●Outline of SOC

Company Name

Kyocera Showa Optronics Co., Ltd.

Representative

Minoru Hijikawa, President

Establishment

1954 (Established as Showa Optical Co., Ltd.)

Location

Head Office: Setagaya-ku, Tokyo

Yokohama Office: Midori-ku, Yokohama City, Kanagawa Prefecture

Capital stock

50 million yen

Number of Employees

Approximately 230

For more information and Product Images of SOC, please visit:
https://global.kyocera.com/news/2020/0304_ddop.html

About KYOCERA
Kyocera Corporation (TOKYO:6971) (https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones. During the year ended March 31, 2019, the company’s consolidated net sales totaled 1.62 trillion yen (approx. USD14.6 billion). Kyocera appears on the “Derwent Top 100 Global Innovators 2018-19” list by Clarivate Analytics and is ranked #655 on Forbes magazine’s 2019 “Global 2000” list of the world’s largest publicly traded companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005221/en/

CONTACT

KYOCERA Corporation (Japan)

Corporate Communications

Kenichi Hara, +81-(0)75-604-3416

webmaster.pressgl@kyocera.jp

Fax: +81-(0)75-604-3516

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease